

## Review Article

# Perspective of Pneumonia in the Health-Care Setting

### ABSTRACT

Pneumonia is a major worldwide health issue, impacting millions of individuals annually and leading to a significant number of hospitalizations and fatalities. Pneumonia is the leading infectious cause of mortality in children globally, responsible for almost 15% of all fatalities in children under 5 years old, as stated by the World Health Organization (WHO). Pneumonia is a prominent reason for hospitalization in the United States, resulting in around 1.5 million hospital admissions annually. Pneumonia is most prevalent in the elderly population, especially those who are 65 years old and above, and persons with preexisting medical disorders such as chronic obstructive pulmonary disease (COPD), heart disease, diabetes, or a compromised immune system. Pneumonia can vary in severity, ranging from a minor case that can be managed at home to a severe and life-threatening infection that necessitates hospitalization and intense medical care. The symptoms and severity of pneumonia might vary based on the underlying cause, the individual's age and overall health status, and other factors. Pneumonia is a severe respiratory infection that can be caused by several pathogens, such as bacteria, viruses, fungi, and unusual microorganisms. It is defined by the presence of inflammation in the alveoli, which are the small air sacs in the lungs responsible for gas exchange. This inflammation can result in the buildup of fluid or pus, which can hinder the lungs' functionality and impede the body's capacity to obtain sufficient oxygen.

*Keywords: Pneumonia, Health-Care Setting, Perspective.*

### 1. INTRODUCTION

Pneumonia is a severe respiratory infection that can be caused by several pathogens, such as bacteria, viruses, fungi, and unusual microorganisms. It is defined by the presence of inflammation in the alveoli, which are the small air sacs in the lungs responsible for gas exchange. This inflammation can result in the buildup of fluid or pus, which can hinder the lungs' functionality and impede the body's capacity to obtain sufficient oxygen. Pneumonia can vary in severity, ranging from a minor case that can be managed at home to a severe and life-threatening infection that necessitates hospitalization and intense medical care. The symptoms and severity of pneumonia might vary based on the underlying cause, the individual's age and overall health status, and other factors[1-8].

### 2. EPIDEMIOLOGY

Pneumonia is a major worldwide health issue, impacting millions of individuals annually and leading to a significant number of hospitalizations and fatalities. Pneumonia is the leading infectious cause of mortality in children globally, responsible for almost 15% of all fatalities in children under 5 years old, as stated by the World Health Organization (WHO). Pneumonia is a prominent reason for hospitalization in the United States, resulting in around 1.5 million hospital admissions annually. Pneumonia is most prevalent in the elderly population, especially those who are 65 years old and above, and persons with preexisting medical disorders such as chronic obstructive pulmonary disease (COPD), heart disease, diabetes, or a compromised immune system. Specific demographic groups face a higher susceptibility to pneumonia, including Elderly individuals, particularly those who are 65 years of age or

older, Toddlers (particularly those below 2 years old), Individuals who have long-term medical issues such as chronic obstructive pulmonary disease (COPD), heart disease, and diabetes, Individuals who have a compromised immune system, such as those with human immunodeficiency virus HIV/Acquired, immunodeficiency syndrome, AIDS, cancer, or who have undergone organ transplants, Individuals who smoke and those with a past of alcohol abuse, Pneumonia imposes a substantial economic burden, with both direct and indirect expenditures amounting to billions of dollars each year in the United States alone. The expenses associated with hospitalization and treatment for severe instances of pneumonia can be notably high, emphasizing the significance of prevention and early intervention[9-17].

### **3. PATHOPHYSIOLOGY**

Pneumonia formation entails intricate interactions between the host's immune system and the invading virus. When an individual breathes in or inhales dangerous bacteria, it stimulates the immune system, causing the activation of different inflammatory pathways. Pneumonia begins with the pathogen attaching to the cells lining the respiratory system, and then invading and reproducing within the lungs. This process can result in the release of several inflammatory mediators, such as cytokines and chemokines, which subsequently attract and stimulate immune cells, including neutrophils, macrophages, and lymphocytes. As the immune system attempts to fight the infection, the arrival of these immune cells and the subsequent inflammation can cause fluid and cellular debris to build up in the alveoli. Pneumonia can hinder the lungs' capacity to effectively exchange oxygen and carbon dioxide, leading to the distinctive symptoms of cough, fever, and respiratory distress. The precise pathophysiological pathways may differ based on the specific type of pathogen implicated. For instance, bacterial pneumonia is frequently identified by the development of a concentrated inflammatory exudate inside the alveoli, whereas viral pneumonia may be linked to a broader alveolar injury and fluid accumulation. In more severe instances, the inflammation and accumulation of fluid can advance to respiratory failure, sepsis, and other potentially fatal consequences. Gaining a comprehensive understanding of the fundamental pathophysiological mechanisms is essential to devise precise therapeutic approaches and enhance patient prognoses[6,9,18,19].

### **4. ETIOLOGY**

Pneumonia can result from several pathogens, such as bacteria, viruses, fungus, and unusual microorganisms. The precise cause of pneumonia might differ according on the environment in which the infection is contracted, as well as the person's age, existing medical conditions, and other variables that increase the risk. The predominant etiologies of pneumonia in the healthcare setting encompass: Bacterial pneumonia is caused by the bacterium *Streptococcus pneumoniae*, *Haemophilus influenzae* *Staphylococcus aureus*, *Klebsiella pneumoniae* is a kind of bacteria, *Pseudomonas aeruginosa* is the name of a specific type of bacteria, *Legionella pneumophila* is a kind of bacteria, Viral pneumonia is caused by influenza viruses, Respiratory syncytial virus (RSV), Adenovirus SARS-CoV-2, the pathogen responsible for the development of COVID-19, Fungal pneumonia is caused by a specific type of fungus called *Pneumocystis jirovecii*, which was previously known as *Pneumocystis carinii*, The mentioned species are *Aspergillus* and *Candida*, Atypical pneumonia: *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, *Coxiella burnetii* is the pathogen responsible for causing Q fever. The prevalence of these pathogens can differ based on the hospital environment, patient demographic, and regional epidemiological trends. In addition, healthcare-associated pneumonia (HCAP), which encompasses pneumonia acquired in long-term care facilities or within 90 days of hospital discharge, may entail a distinct range of causative agents in comparison to community-acquired pneumonia, Determining the root cause of pneumonia is essential for selecting the right antimicrobial treatment and enhancing patient results. Often, a comprehensive assessment involving

clinical, radiographic, and microbiological examinations is required to identify the precise causal agent[20-29].

## **5. DIAGNOSIS**

Precise and prompt diagnosis of pneumonia is essential for directing suitable therapy and enhancing patient outcomes in healthcare settings. The diagnostic technique usually entails a blend of clinical evaluation, radiographic imaging, and microbiological tests.

1. Clinical assessment: Symptom evaluation: Examination of fever, cough, sputum production, chest discomfort, dyspnea, and exhaustion. Physical examination includes auscultation of the lungs, assessment of vital signs, and evaluation of risk factors. Evaluation of risk factors includes characteristics such as older age, pre-existing medical illnesses, impaired immune system, and contact with invasive medical devices or healthcare settings.

2. Radiographic imaging: Chest radiography is the preferred initial method for detecting pulmonary infiltrates and consolidations. Computed tomography (CT) scans are employed to obtain more comprehensive and precise data, particularly when chest radiography is ambiguous or to detect problems. Ultrasonography is becoming increasingly useful for assessing pneumonia, especially in patients who are on mechanical ventilation.

3. Microbiological testing involves the collection and analysis of sputum samples to identify the specific organism responsible for the infection. Blood cultures are valuable in identifying bacteremia linked to pneumonia, especially in cases of high severity. Molecular diagnostics employ techniques such as Polymerase Chain Reaction (PCR) to swiftly identify the presence of particular respiratory infections. Rapid antigen detection tests offer prompt findings for the diagnosis of specific viral and bacterial pathogens, such as influenza and *Streptococcus pneumoniae*. When interpreting diagnostic test findings, it is important to take into account the patient's clinical symptoms, any existing medical conditions, and epidemiological considerations, such as the patterns of microbial resistance in the local area. An effective diagnosis of pneumonia in healthcare settings often requires a combination of clinical, radiographic, and microbiological data. Conducting a prompt and thorough diagnostic examination is essential in order to start the right antimicrobial treatment, customize management approaches, and enhance patient outcomes. Healthcare facilities must design and frequently evaluate their diagnostic algorithms to guarantee prompt and efficient diagnosis of pneumonia, which is crucial for optimal patient care and infection prevention[2,30-35].

## **6. TYPES OF PNEUMONIA**

Pneumonia can be categorized into various categories depending on the etiological agent, the acquisition context, and the severity of the disease. The primary classifications of pneumonia and their accompanying therapeutic strategies are as follows

### **6.1 COMMUNITY-ACQUIRED PNEUMONIA**

It is type of pneumonia that is acquired outside of a healthcare setting. Cause: Common bacterial pathogens, such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Mycoplasma pneumoniae*, are the usual causes of this condition. Treatment: The initial antibiotic treatment is determined by the patient's risk factors and the severity of their sickness. This is followed by a more specific antibiotic treatment depending on the results of microbiological tests[36-38].

### **6.2 HOSPITAL-ACQUIRED PNEUMONIA**

Cause: Frequently attributed to highly resistant microorganisms, including *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Acinetobacter* species, and *Klebsiella pneumoniae*. Treatment: Initiate empirical administration of a wide range of antibiotics, followed by adjustment based on microbiological findings and clinical improvement[39,40].

### **6.3 HEALTHCARE-ASSOCIATED PNEUMONIA**

Cause: Healthcare-associated pneumonia may be caused by a combination of infections that are acquired in the community and those that are more resistant and associated with healthcare settings[41].

### **6.4 VIRAL PNEUMONIA**

caused by many viruses, including influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 (the virus responsible for COVID-19). Treatment: Supportive care is administered, with the inclusion of antiviral drugs in some instances (such as oseltamivir for influenza)[42-45].

### **6.5 FUNGAL PNEUMONIA**

Cause: Resulting from opportunistic fungus, including *Pneumocystis jirovecii*, *Aspergillus* species, and *Candida* species. Treatment: Targeted administration of antifungal medications, frequently in conjunction with immunosuppressive drugs, for those with weakened immune systems[31,46].

### **6.6 ASPIRATION PNEUMONIA**

caused by the inhalation of stomach contents and is commonly observed in people with swallowing difficulties or neurological disorders. Treatment: Administering antimicrobial therapy to target the material that was aspirated, along with implementing measures to address the root cause of the aspiration.[47-49].

## **6. PREVENTION**

Ensuring the prevention of pneumonia in hospital settings is an essential component of safeguarding patient well-being and promoting public health. Various evidence-based measures have been put into practice to decrease the occurrence and consequences of pneumonia, specifically among populations and healthcare facilities that are at a higher risk. Vaccination is a highly efficient method for preventing pneumonia. The pneumococcal conjugate vaccine (PCV) and the pneumococcal polysaccharide vaccine (PPSV) are advised for vulnerable populations, such as the elderly, persons with chronic medical conditions, and immunocompromised patients. These vaccines have demonstrated a substantial decrease in the occurrence of pneumococcal pneumonia and its related consequences. Furthermore, it is advisable to receive the influenza vaccination every year for persons who are 6 months of age or older, as it can effectively reduce the risk of developing viral pneumonia caused by influenza viruses. It is crucial to prioritize achieving a high vaccination rate among healthcare staff and inhabitants of long-term care facilities to safeguard vulnerable individuals.

**Methods to Prevent the Spread of Infections** It is essential to establish strong infection control protocols in healthcare facilities to effectively limit the spread of pneumonia-causing bacteria. Essential tactics include Hand hygiene is crucial for minimizing the transmission of respiratory pathogens. This can be achieved by either thoroughly washing hands with soap and water or by using alcohol-based hand sanitizers. Personal protective equipment (PPE) refers to the specialized gear and clothing used by individuals to protect themselves from potential hazards or risks in their environment. Healthcare professionals must utilize suitable personal protective equipment (PPE), including masks, gowns, and gloves while providing care for patients who are suspected or confirmed to have pneumonia. Sanitation and sterilization of the environment: Regular cleaning and disinfection of places where patients receive care, as well as equipment and surfaces that are frequently touched, can effectively remove possible sources of infection. Isolation and cohorting: Patients displaying symptoms or diagnosed with pneumonia should be placed in suitable isolation, and healthcare

personnel should adhere to established protocols to avoid the spread of infection. Antimicrobial stewardship involves the implementation of strong systems to effectively manage the use of antimicrobial drugs. These programs play a crucial role in reducing the emergence and transmission of bacteria that are resistant to antibiotics, which are a significant cause of pneumonia acquired in healthcare settings. Timely detection and proactive intervention Swift identification and proper treatment of pneumonia are crucial for enhancing patient results. Healthcare personnel must be alert in recognizing the initial indications and symptoms of pneumonia, including elevated body temperature, coughing, and difficulty breathing, and promptly commence suitable diagnostic examinations and therapy.

Methods that encourage prompt recognition and intervention at an early stage encompass Regular surveillance of vital signs, respiratory condition, and other clinical indicators that can aid in the early detection of pneumonia during routine patient monitoring. Diagnostic testing involves the use of rapid diagnostic tests, such as sputum cultures, molecular assays, and biomarkers. These tests help in quickly identifying the specific pathogen responsible for the infection and guide targeted antibiotic therapy. Prompt initiation of antibiotic administration is recommended when pneumonia is suspected. Empiric antibiotic therapy should be started without delay, following recognized guidelines and considering local resistance patterns. Optimal therapy of pneumonia and prevention of complications can be achieved by involving a multidisciplinary team consisting of physicians, nurses, respiratory therapists, and infection control specialists. Education for Patients and Staff. It is essential to provide education to patients, their families, and healthcare personnel regarding the prevention and treatment of pneumonia including Patient education: Disseminating crucial knowledge to patients and their caregivers regarding the significance of pneumonia prevention, identifying symptoms, and promptly seeking medical assistance. Training for healthcare workers: Providing thorough education to healthcare staff regarding pneumonia risk factors, preventative techniques, and proper management protocols. Continuous quality improvement involves the implementation of continual monitoring, feedback, and instructional programs to strengthen best practices and identify areas for improvement in pneumonia prevention and control. Specialized care environments: Creating specialized care environments in healthcare settings, such as respiratory care units or wards dedicated to pneumonia, might enhance patient outcomes. These facilities typically feature specialized personnel, state-of-the-art diagnostic and treatment capabilities, and a strong emphasis on evidence-based methods, all of which can improve the quality of care for patients with pneumonia[30,50-54].

#### **14. CONCLUSION**

Pneumonia continues to be a major issue in hospital settings, significantly affecting patient outcomes, healthcare expenses, and resource usage. Gaining knowledge on the epidemiology, pathophysiology, and etiological factors that contribute to pneumonia is essential in order to create successful methods for preventing and managing the disease. The comprehensive strategy for preventing pneumonia in healthcare settings, which encompasses immunization, infection control measures, prompt identification and intervention, and education of patients and staff, has shown promise in reducing both the frequency and severity of pneumonia cases. Nevertheless, the persistent obstacles, such as the advent of bacteria that are resistant to antibiotics and the ever-changing nature of respiratory infections, need a constant need for adjustment and creativity in the management of pneumonia. Effective collaboration among healthcare professionals, infection control specialists, public health authorities, and researchers is crucial for enhancing the prevention and management of pneumonia in healthcare settings. To reduce the impact of chronic respiratory illness and enhance patient outcomes, it is crucial to continue investing in research, developing new diagnostic tools and antimicrobial medicines, and implementing

comprehensive, evidence-based measures. Ultimately, a thorough comprehension of pneumonia in the healthcare environment, together with a diverse strategy for prevention and treatment, is vital for improving patient safety, decreasing healthcare-associated infections, and fostering improved patient results. Healthcare systems can effectively manage and avoid this important respiratory concern by maintaining vigilance, responding to evolving issues, and following best practices.

## REFERENCES

1. Funk GC, Nell C, Pokieser W, Thaler B, Rainer G, Valipour A: Organizing pneumonia following Covid19 pneumonia. *Wien Klin Wochenschr.* 2021, 133:979-982. 10.1007/s00508-021-01852-9
2. Geppert EF: Chronic and recurrent pneumonia. *Semin Respir Infect.* 1992, 7:282-288.
3. Hooven TA, Polin RA: Pneumonia. *Semin Fetal Neonatal Med.* 2017, 22:206-213. 10.1016/j.siny.2017.03.002
4. Leedom JM: Pneumonia. Patient profiles, choice of empiric therapy, and the place of third-generation cephalosporins. *Diagn Microbiol Infect Dis.* 1992, 15:57-65. 10.1016/0732-8893(92)90057-z
5. Orens JB, Sitrin RG, Lynch JP, 3rd: The approach to nonresolving pneumonia. *Med Clin North Am.* 1994, 78:1143-1172. 10.1016/s0025-7125(16)30124-9
6. Panciera RJ, Confer AW: Pathogenesis and pathology of bovine pneumonia. *Vet Clin North Am Food Anim Pract.* 2010, 26:191-214. 10.1016/j.cvfa.2010.04.001
7. Singh V, Aneja S: Pneumonia - management in the developing world. *Paediatr Respir Rev.* 2011, 12:52-59. 10.1016/j.prrv.2010.09.011
8. Torres A, Cilloniz C, Niederman MS, et al.: Pneumonia. *Nat Rev Dis Primers.* 2021, 7:25. 10.1038/s41572-021-00259-0
9. Anandan L, Carasco C, Mori L, Margaritopoulos GA: What you need to know about: organising pneumonia. *Br J Hosp Med (Lond).* 2022, 83:1-8. 10.12968/hmed.2021.0451
10. Heath PT: Epidemiology and bacteriology of bacterial pneumonias. *Paediatr Respir Rev.* 2000, 1:4-7. 10.1053/prrv.2000.0001
11. Mayaud C, Parrot A, Houacine S, Denis M, Akoun G: [Epidemiology of micro-organisms responsible for community-acquired pneumonia]. *Rev Pneumol Clin.* 1992, 48:101-110.
12. Roselle GA, Danko LH, Kralovic SM, Simbartl LA, Hilley J, Tryhus P: A six-year epidemiologic review of pneumonia in Department of Veterans Affairs facilities. *Mil Med.* 1999, 164:293-297.
13. Segreti J, Bone RC: Overwhelming pneumonia. *Dis Mon.* 1987, 33:1-59.
14. Wang Y, Ma L, Li Y, Li Y, Zheng Y, Zhang X: Epidemiology and clinical characteristics of pathogens positive in hospitalized children with segmental/lobar pattern pneumonia. *BMC Infect Dis.* 2020, 20:205. 10.1186/s12879-020-4938-7
15. Carden DL, Gibb KA: Pneumonia and lung abscess. *Emerg Med Clin North Am.* 1983, 1:345-370.
16. Nissen MD: Congenital and neonatal pneumonia. *Paediatr Respir Rev.* 2007, 8:195-203. 10.1016/j.prrv.2007.07.001
17. Schlepner CJ, Cobb DK: A study of the etiologies and treatment of nosocomial pneumonia in a community-based teaching hospital. *Infect Control Hosp Epidemiol.* 1992, 13:515-525. 10.1086/646591
18. Jain V, Vashisht R, Yilmaz G, Bhardwaj A: Pneumonia Pathology. *StatPearls.* StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies. Disclosure: Rishik Vashisht declares no relevant financial relationships with ineligible companies. Disclosure: Gizem Yilmaz declares no relevant financial relationships with ineligible companies. Disclosure: Abhishek Bhardwaj declares no relevant financial relationships with ineligible companies.; 2024.
19. Troillet N, Francioli P: [Pneumonia in patients with mechanical ventilation: physiopathology and prevention]. *Schweiz Med Wochenschr.* 1994, 124:236-240.
20. Abdulhadi B, Kiel J: Mycoplasma Pneumonia. *StatPearls.* StatPearls Publishing

- Copyright © 2024, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies. Disclosure: John Kiel declares no relevant financial relationships with ineligible companies.; 2024.
21. Arenas-Jiménez JJ, García-Garrigós E, Ureña Vacas A, Sirera Matilla M, Feliu Rey E: Organizing pneumonia. *Radiologia (Engl Ed)*. 2022, 64 Suppl 3:240-249. 10.1016/j.rxeng.2022.08.002
  22. Ashurst JV, Dawson A: Klebsiella Pneumonia. StatPearls. StatPearls Publishing  
Copyright © 2024, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies. Disclosure: Adam Dawson declares no relevant financial relationships with ineligible companies.; 2024.
  23. Gautam J, Krawiec C: Chlamydia Pneumonia. StatPearls. StatPearls Publishing  
Copyright © 2024, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies. Disclosure: Conrad Krawiec declares no relevant financial relationships with ineligible companies.; 2024.
  24. Niederman MS, Cilloniz C: Aspiration pneumonia. *Rev Esp Quimioter*. 2022, 35 Suppl 1:73-77. 10.37201/req/s01.17.2022
  25. Pahal P, Penmetsa GK, Modi P, Sharma S: Eosinophilic Pneumonia. StatPearls. StatPearls Publishing  
Copyright © 2024, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies. Disclosure: Gopi Penmetsa declares no relevant financial relationships with ineligible companies. Disclosure: Pranav Modi declares no relevant financial relationships with ineligible companies. Disclosure: Sandeep Sharma declares no relevant financial relationships with ineligible companies.; 2024.
  26. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR: Viral pneumonia. *Lancet*. 2011, 377:1264-1275. 10.1016/s0140-6736(10)61459-6
  27. Sattar SBA, Nguyen AD, Sharma S: Bacterial Pneumonia. StatPearls. StatPearls Publishing  
Copyright © 2024, StatPearls Publishing LLC., Treasure Island (FL) with ineligible companies. Disclosure: Andrew Nguyen declares no relevant financial relationships with ineligible companies. Disclosure: Sandeep Sharma declares no relevant financial relationships with ineligible companies.; 2024.
  28. Shebl E, Gulick PG: Nosocomial Pneumonia. StatPearls. StatPearls Publishing  
Copyright © 2024, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies. Disclosure: Peter Gulick declares no relevant financial relationships with ineligible companies.; 2024.
  29. Thomas CF, Jr., Limper AH: Pneumocystis pneumonia. *N Engl J Med*. 2004, 350:2487-2498. 10.1056/NEJMra032588
  30. Carden DL, Smith JK: Pneumonias. *Emerg Med Clin North Am*. 1989, 7:255-278.
  31. Fels AO: Bacterial and fungal pneumonias. *Clin Chest Med*. 1988, 9:449-457.
  32. Lechartier B, Prella M, Manuel O, Nicod LP: [How to handle a non-resolving pneumonia?]. *Rev Med Suisse*. 2016, 12:1942-1947.
  33. Miyashita N: Atypical pneumonia: Pathophysiology, diagnosis, and treatment. *Respir Investig*. 2022, 60:56-67. 10.1016/j.resinv.2021.09.009
  34. Rodnick JE, Gude JK: Diagnosis and antibiotic treatment of community-acquired pneumonia. *West J Med*. 1991, 154:405-409.
  35. Speich R, Ruef C, Russi EW: [Diagnosis and therapy of community-acquired pneumonia]. *Schweiz Med Wochenschr*. 1993, 123:1846-1856.
  36. Mayer KH, Hochreiter K: [Community-acquired pneumonia]. *Acta Med Austriaca*. 1993, 20:124-126.
  37. Meyer RD, Finch RG: Community-acquired pneumonia. *J Hosp Infect*. 1992, 22 Suppl A:51-59. 10.1016/s0195-6701(05)80007-6
  38. Seeger A, Rohde G: [Community-acquired pneumonia]. *Dtsch Med Wochenschr*. 2023, 148:335-341. 10.1055/a-1940-8944
  39. Hospital-acquired pneumonias. *Semin Respir Infect*. 1987, 2:1-81.
  40. Jakubec P, Křenková A, Kolek V: [Hospital-acquired pneumonias]. *Vnitr Lek*. 2018, 63:776-785.
  41. Komiya K, Ishii H, Kadota J: Healthcare-associated Pneumonia and Aspiration Pneumonia. *Aging Dis*. 2015, 6:27-37. 10.14336/ad.2014.0127
  42. Clausen CL, Benfield T: [Viral pneumonia in immunocompetent adults]. *Ugeskr Laeger*. 2021, 183.
  43. Latham-Sadler BA, Morell VW: Viral and atypical pneumonias. *Prim Care*. 1996, 23:837-848. 10.1016/s0095-4543(05)70365-1
  44. Reimann HA: Viral pneumonias. *J Am Med Assoc*. 1956, 161:1078-1079. 10.1001/jama.1956.02970110044012
  45. Sinanotis CA: Viral pneumoniae in children: incidence and aetiology. *Paediatr Respir Rev*. 2004, 5 Suppl A:S197-200. 10.1016/s1526-0542(04)90037-1
  46. Davies SF: Fungal pneumonia. *Med Clin North Am*. 1994, 78:1049-1065. 10.1016/s0025-7125(16)30119-5

47. Cambell-Taylor I: Aspiration pneumonia. *N Engl J Med*. 2001, 344:1869; author reply 1869-1870.
48. Ebihara S, Miyagi M, Otsubo Y, Sekiya H, Ebihara T: Aspiration Pneumonia: A Key Concept in Pneumonia Treatment. *Intern Med*. 2021, 60:1329-1330. 10.2169/internalmedicine.6576-20
49. Pennza PT: Aspiration pneumonia, necrotizing pneumonia, and lung abscess. *Emerg Med Clin North Am*. 1989, 7:279-307.
50. Crnich CJ, Safdar N, Maki DG: The role of the intensive care unit environment in the pathogenesis and prevention of ventilator-associated pneumonia. *Respir Care*. 2005, 50:813-836; discussion 836-818.
51. Crouch TW, Higuchi JH, Coalson JJ, Johanson WG, Jr.: Pathogenesis and prevention of nosocomial pneumonia in a nonhuman primate model of acute respiratory failure. *Am Rev Respir Dis*. 1984, 130:502-504. 10.1164/arrd.1984.130.3.502
52. Irigaray R, Dorca J: [Atypical pneumonias]. *Arch Bronconeumol*. 1996, 32:187-195. 10.1016/s0300-2896(15)30785-7
53. Mathewson HS: Preventing posttraumatic pneumonia. *Crna*. 1995, 6:114-117.
54. Vila-Corcoles A, Ansa X, Ochoa-Gondar O, Satue E, de Diego C, Rodriguez-Blanco T: Pneumococcal pneumonia in adults 60 years or older: Incidence, mortality and prevention. *Med Clin (Barc)*. 2016, 146:199-202. 10.1016/j.medcli.2015.09.015

UNDER PEER REVIEW